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ABSTRACT
A demonstration of cardiovascular safety is
mandatory for all newly developed glu-
cose-lowering agents, including insulin ana-
logues. The vascular benefit of insulin is evident
from the Diabetes Control and Complication
Trial (DCCT) and United Kingdom Prospective
Diabetes Study (UKPDS), and the cardiovascular
safety of insulin glargine has been demon-
strated in individuals with newly diagnosed
diabetes or prediabetes in the ORIGIN trial
(Outcome Reduction with an Initial Glargine
Intervention). The top-line results of DEVOTE
(Trial Comparing Cardiovascular Safety of
Insulin Degludec vs. Insulin Glargine in
Patients with Type 2 Diabetes at High Risk of
Cardiovascular Events) have proven the cardio-
vascular safety of insulin degludec in persons
with type 2 diabetes. In this commentary I dis-
cuss the interrelationship of insulin and car-
diovascular health, while comparing the results
of DEVOTE and ORIGIN.
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Insulin is a well-established treatment for both
type 1 and type 2 diabetes and has been in use
now for nearly a century. During this time, the
source, structure, purity and delivery of insulin
has changed significantly. What has not chan-
ged, however, is the ability of insulin to control
blood glucose, improve quality of life, avoid
complications and save lives. The ability of
insulin to prevent micro- and micro-vascular
complications has been demonstrated in two
landmark trials, namely the Diabetes Control
and Complication Trial (DCCT) and the United
Kingdom Prospective Diabetes Study (UKPDS)
[1, 2].
While the above-mentioned benefits of
insulin are not disputed, the occurrence of side
effects, such as weight gain and hypoglycaemia,
did lead to concerns about the cardiovascular
safety of this drug [3–5]. One large study
reported that intensive and rapid glycaemic
control measures using insulin as one of many
interventional components increased the risk of
cardiovascular events and all-cause mortality
[3]. The authors, however, did comment that
the study was not designed to identify the par-
ticular component causing increased events. A
meta-analysis also showed that fasting hyper-
insulinemia is significantly associated with
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cardiovascular mortality in non-diabetic adults
[6]. However, this hyperinsulinemia may be due
to insulin resistance, which itself is linked to
cardiovascular dysfunction.
Certain insulin analogues were also thought
to be linked to increased cancer risk because of
their growth-promoting properties [7–12].
Unfounded concerns about the ‘‘pushing ‘‘of
insulin by manufacturers added fuel to fire [13].
These uncertainties led to a debate on whether
insulin use to achieve euglycemia in type 2
diabetes follows the dictum ‘primum succur-
rere’ (first hasten to help) without respecting
the philosophy of ‘primum non nocere’ (first do
not harm). However, these issues, raised by
non-specialists in the field, have effectively
been put to rest with the ORIGIN and DEVOTE
trials.
The ORIGIN trial (Outcome Reduction with
an Initial Glargine Intervention) showed insulin
glargine to have cardiovascular safety when
administered to participants with newly diag-
nosed type 2 diabetes or prediabetes [14]. The
authors of the ORIGIN trial highlighted the
large difference in insulin use between the
insulin glargine and control group, as well as
the glycaemic equipoise achieved between
them. Hence, the cardiovascular safety demon-
strated in the intervention (glargine) group
related more to glargine or insulin per se than to
good glycaemic control.
The DEVOTE trial Trial (Comparing Cardio-
vascular Safety of Insulin Degludec vs. Insulin
Glargine in Patients with Type 2 Diabetes at
High Risk of Cardiovascular Events) studied
7637 participants with type 2 diabetes and a
high cardiovascular risk profile who were being
treated with one or more oral or
injectable anti-diabetic agent, with a glycated
haemoglobin A1c (HbA1c) of [7.0%. Partici-
pants with a HbA1c of\7.0% were included in
the trial if their current basal insulin require-
ment was[20 U/day. All participants were ran-
domized in a double-blinded manner, in a 1:1
ratio, to either an insulin degludec ? standard
of care arm or an insulin glargine ? standard of
care arm. They were seen weekly for 2 weeks,
monthly for 6 months and quarterly for the rest
of the trial [15]. This trial design differed from
ORIGIN with respect to inclusion criteria, trial
structure and choice of comparator arm and
frequency of follow-up (Table 1). It must be
noted that ORIGIN had a placebo arm, while
DEVOTE used an active comparator arm.
The DEVOTE trial included participants with
a longer duration of diabetes and a higher car-
diovascular risk profile. The inclusion criteria
were reflective of a real world diabetes outdoor
clinic which included participants of a similar
background who could be initiated on (or swit-
ched to) a basal insulin analogue. The primary
endpoint of the study, i.e. the MACE composite
outcome of first occurrence of cardiovascular
death, non-fatal stroke and myocardial infarc-
tion, showed a hazard ratio of 0.91 in favour of
degludec relative to insulin glargine U100, but
this difference was not statistically significant
[16]. Thus, degludec demonstrated cardiovascu-
lar safety, relative to glargine, allaying concerns
about its use in type 2 diabetes patients at risk of
cardiovascular disease.
The secondary endpoint, i.e. hypoglycaemia,
occurred in fewer participants on degludec than
in those on glargine. While 27% fewer partici-
pants in the degludec arm experienced an epi-
sode of severe hypoglycaemia, there was a 40%
reduction in the number of total episodes of
adjudicated severe hypoglycaemia and a 54%
relative reduction in the rate of nocturnal severe
hypoglycaemia, with all these difference
achieving statistical significance. These results
are concordant with those reported in the
BEGIN and BOOST clinical trial programmes of
insulin degludec and degludec aspart [17, 18].
Hypoglycaemia per se is a risk factor for
cardiovascular mortality and is known to impair
quality of life [19, 20]. Hence, avoidance of
hypoglycaemia is one of the aims of safe and
effective diabetes care and is included in the
glycaemic pentad [21].
While detailed data of the DEVOTE trial will
be reported at a later time, the top-line results
are encouraging. The trial provides evidence
that one can use insulin degludec to achieve
better glycaemic control without fear of hypo-
glycaemia and without fear of cardiovascular
adverse effects. This will encourage the timely
use of insulin in persons with type 2 diabetes,
including those with cardiovascular risk factors.
In the debate between two contrasting
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philosophies of action, ‘Primum succurrere’,
and ‘Primum non nocere’, degludec proves its
DEVOTion to diabetes care: Auxiliendo, Pri-
mum non nocere.
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